NCT02198339已完成2 期
A Phase II a, Double-Blind, Randomised, Group Sequential Adaptive Assignment Design Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Seven Fixed Doses of Intravenous BIBN 4096 BS Ranging From 0.1 to 10.0 mg Versus Placebo in the Treatment of a Single Attach of Acute Migraine Headache
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 126
- 主要终点
- Headache Response measured on a four-point scale
研究概览
简要总结
Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS in patients with a single acute migraine attack with or without aura
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Man and women with an acute onset of acute migraine headache with or without aura of moderate to severe intensity
- •Established diagnosis of migraine (with or without aura) according to International Headache Society (IHS) criteria for >= 1 year; age of onset <= 50 years
- •Current age is 18-65 years
- •Study drug treatment to begin in less than 6 hours of the onset of migraine headache which is not spontaneously improving. Time of awakening with a migraine headache is considered as time of onset provided no headache was present prior to sleep
- •History of 1 to 6 migraine headaches per month for the preceding 6 months
- •Ability to give written informed consent in accordance with International Committee on Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation
排除标准
- •Use of prescription and non-prescription medications for migraine prophylaxis within 2 weeks prior to treatment including Selective Serotonin Reuptake Inhibitors (SSRIs) (except fluoxetine which should have a 6 weeks washout), flunarizine (which should have a 4 week washout) and Mono-amino-oxidase-inhibitors drugs (MAOIs)
- •Use of paracetamol (acetaminophen), aspirin, Non-steroidal anti-inflammatory drugs (NSAIDS), barbiturates or anti-emetics within 12 hours of taking study drug or of any 'triptan', ergotamine preparation or opiate analgesics within 48 hours prior to study drug administration or the use of analgesics > 10 days/months
- •History of significant medical (i.e. coronary artery disease by history, renal failure), neurological (including epilepsy and structural brain lesions) or psychiatric disorders
- •History, clinical evidence or screening or baseline electrocardiogram suggestive of cardiovascular disease including ischemic heart disease, Prinzmetal angina, coronary vasospasm, history of atherosclerotic heart disease of cardiac arrhythmia
- •History of known hypertension
- •History of basilar, ophthalmoplegic or hemiplegic migraine headaches or non-migraine headaches (e.g. tension-type headaches) occurring on average >= 10 days per month for the preceding 6 months
- •History of treatment resistance migraine attacks defined as a lack of response to a range of commonly used acute anti-migraine compounds
- •Females who are nursing or pregnant (as determined by a serum pregnancy test at screening and a urine pregnancy test at baseline) or of childbearing potential (any woman who is not at least 1 year post-menopausal or surgically sterile is considered to be of childbearing potential) and not using a medically approved method of birth control as defined by local country requirements
- •Baseline systolic BP >= 160 mmHg or diastolic BP >= 100 mmHg
- •Any daily intake of prescribed medication within 2 weeks prior to randomization for diseases in the investigator's judgment that would contraindicate participation in the trial
- •History of Raynauds' disease
- •A recent history (six months) of current evidence of alcohol or recreational drug abuse as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM- IV) (R97-1072)
- •Post or present medical conditions that would keep administration of study mediation from being in the patient's best interest in the judgment of the clinical investigator
- •Unwillingness or inability to comply with the protocol (e.g. the patient cannot read or write and does not have another person to assist in completing the diary; the patient cannot be followed for 1 weeks). Patients unable to give informed consent are to be excluded from participation in the trial. Patients with legally appointed custodian can not be enrolled in the trial. In case of doubt an independent psychiatrist should testify that the patient is able to give informed consent
- •Use of another investigational drug within a time span of at least ten half-lives but never less than 1 month. Concurrent participation in another investigational protocol
- •Prior exposure to BIBN 4096 BS
研究组 & 干预措施
BIBN 4096 BS - ranging dose
Experimental
sequential adaptive design, allocation of verum treated patients to dose groups not fixed in advance
IV infusion over 10 minutes
干预措施: BIBN 4096 BS (Drug)
Placebo
Placebo Comparator
IV infusion over 10 minutes
干预措施: Placebo (Drug)
结局指标
主要结局
Headache Response measured on a four-point scale
时间窗: 2 hours post start of infusion
次要结局
- Qualified Headache Response measured on four-point scale(up to 24 hours post start of infusion)
- Worsening/Recurrence of Headache pain(2 - 24 hours post start of infusion)
- Headache Free measured on a four-point scale(30 min, 1, 2, 4 and 24 hours post start of infusion)
- Number of patients with adverse events(up to day 9)
- AUC (Area under the concentration time curve of the analyte in plasma)(up to 4 hours post start of infusion)
- Tmax (Time to maximum concentration of the analyte in plasma)(up to 4 hours post start of infusion)
- Occurence of Meaningful Relief measured by stopwatch(up to 4 hours post start of infusion)
- Use of rescue medication(within 24 hours post start of infusion)
- Headache Response measured on a four-point scale(30 min, 1, 4 and 24 hours post start of infusion)
- Maintenance of Headache Response measured on a four-point scale(up to 24 hours post start of infusion)
- Relief of associated symptoms(30 min, 1, 2, 4 and 24 hours post start of infusion)
- Cmax (Maximum observed concentration of the analyte in plasma)(up to 4 hours post start of infusion)
- Time to sustained Headache Response(up to 24 hours post start of infusion)
- Time to Meaningful Relief measured by stopwatch(up to 4 hours post start of infusion)
- Clinical Disability measured on four-point scale(30 min, 1, 2, 4 and 24 hours post start of infusion)
- Time to use of rescue medication(within 24 hours post start infusion)
研究者
相似试验
已完成
1 期
Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS in Healthy Male VolunteersHealthyNCT02214901Boehringer Ingelheim91
已完成
2 期
BI 1356 BS in Japanese Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT02183324Boehringer Ingelheim72
已完成
1 期
BAX 826 Dose-Escalation Safety StudyHemophilia ANCT02716194Baxalta now part of Shire40
已完成
1 期
BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF SubjectsCystic FibrosisNCT02976519Boehringer Ingelheim64
已完成
2 期
BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type PsoriasisPsoriasisNCT02209753Boehringer Ingelheim182